Alkem Laboratories Sees Sharp Open Interest Surge Amid Bearish Momentum

Open Interest and Volume Dynamics

On 25 Sep 2026, Alkem Laboratories (symbol: ALKEM) recorded an open interest (OI) of 24,382 contracts, up from 21,049 the previous day, marking an increase of 3,333 contracts or 15.83%. This rise in OI was accompanied by a futures volume of 11,851 contracts, reflecting active trading interest in the derivatives market. The combined futures and options value stood at approximately ₹38,474 lakhs, with futures contributing ₹38,310 lakhs and options an overwhelming ₹4,063.8 crores, underscoring the substantial notional exposure in the stock’s derivatives.

The underlying stock closed at ₹5,242, hovering just 3.79% above its 52-week low of ₹5,051. This proximity to the annual low, alongside a two-day consecutive decline totalling a 3.09% loss, highlights the bearish sentiment prevailing among investors. The stock underperformed its Pharmaceuticals & Biotechnology sector by 1.23% on the day, while the broader Sensex managed a marginal gain of 0.05%, indicating sector-specific pressures weighing on Alkem.

Technical Indicators and Market Positioning

Alkem Laboratories is currently trading below all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — signalling a sustained downtrend. The narrow intraday trading range of ₹3 suggests limited price discovery and cautious investor behaviour amid uncertainty. Notably, delivery volumes have plummeted by 59.19% compared to the five-day average, with only 52,880 shares delivered on 24 Sep, indicating waning investor participation in the cash market.

This divergence between rising open interest and falling prices typically points to fresh short positions being established rather than long positions unwinding. Market participants appear to be increasing bearish bets through derivatives, possibly anticipating further downside or hedging existing exposures. The mid-cap stock’s Mojo Score has deteriorated to 44.0, with a downgrade from Hold to Sell on 24 Sep 2026, reflecting a negative outlook from MarketsMOJO’s quantitative assessment.

Implications of Rising Open Interest Amid Declining Prices

The simultaneous rise in open interest and decline in price is a classic indicator of new short positions being built rather than profit-taking by longs. This suggests that traders and institutional investors are positioning for further downside in Alkem Laboratories. The futures value of ₹38,310 lakhs and the enormous options notional value indicate that significant capital is being deployed in derivative contracts, amplifying the stock’s volatility potential.

Given the stock’s mid-cap status with a market capitalisation of ₹62,783.58 crores, liquidity remains adequate for sizeable trades, with the average traded value supporting a trade size of approximately ₹1.93 crores based on 2% of the five-day average. However, the sharp drop in delivery volumes signals that long-term investors may be stepping back, leaving the price action increasingly influenced by short-term speculative flows.

Sectoral and Broader Market Context

Within the Pharmaceuticals & Biotechnology sector, Alkem Laboratories’ underperformance relative to peers and the sector index is notable. While the sector itself has been relatively stable, the stock’s technical weakness and deteriorating fundamentals have led to a downgrade in its Mojo Grade from Hold to Sell. This downgrade, effective 24 Sep 2026, reflects concerns over the company’s near-term prospects and market positioning.

Investors should also consider the broader market environment, where the Sensex has shown resilience with a slight positive return, contrasting with Alkem’s negative momentum. This divergence may indicate stock-specific challenges such as competitive pressures, regulatory risks, or earnings concerns that are not affecting the wider market to the same extent.

Investor Takeaways and Outlook

For investors, the current derivatives activity in Alkem Laboratories signals caution. The increase in open interest amid falling prices and declining delivery volumes suggests that bearish sentiment is gaining ground. Traders should be wary of potential further downside, especially given the stock’s technical weakness below all major moving averages and its proximity to the 52-week low.

While the stock remains liquid enough for active trading, the downgrade to a Sell rating by MarketsMOJO and the deteriorating Mojo Score of 44.0 reinforce the need for prudence. Investors may consider reducing exposure or hedging positions until clearer signs of a reversal or fundamental improvement emerge.

In summary, the surge in open interest in Alkem Laboratories’ derivatives market is a telling indicator of shifting market positioning towards bearish bets. This development, combined with weak price action and falling investor participation, paints a cautious picture for the stock’s near-term trajectory.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today